Back to results
US 11,034,961 B2Granted
Treatment using truncated Trk B and Trk C antagonists
AssigneeOtonomy, Inc.
InventorsHoracio Uri Saragovi, Fabrice Piu
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods, compositions, vectors, and kits comprising an antagonist of a truncated TrkC or a truncated TrkB. Also described herein are methods of treating and/or preventing an otic disease or condition associated with an elevated expression level of a truncated TrkC or truncated TrkB isoform.
Claims21
A pharmaceutical composition comprising:
- a) a nucleic acid polymer that is configured to hybridize to a target sequence of truncated TrkC or truncated TrkB, wherein the nucleic acid polymer is configured to decrease the expression level of the truncated TrkC or truncated TrkB upon administration of the pharmaceutical composition to a patient in need thereof;
- and
- b) a pharmaceutically acceptable excipient or a delivery vehicle, wherein the pharmaceutical composition is formulated for intratympanic injection and comprises poloxamer 407.
A pharmaceutical composition comprising an isolated and purified nucleic acid polymer comprising at least 80%, 85%, 90%, 95%, 99% or 100% sequence identity to a nucleic acid sequence selected from SEQ ID NOs:
- 1-5 and 114-119, wherein the pharmaceutical composition is formulated for intratympanic injection and comprises poloxamer 407.
Dependencies are inferred from the claim text.